Analysis for Health Care Select Sector SPDR Fund
Analysis summary
Health Care Select Sector SPDR Fund (XLV) currently has a total score of 59 points, placing it in the neutral range. The score is made up of Performance (44), Stability (87) and Trend (54). The profile is clearly uneven: Stability stands out while Performance is more neutral.
Performance scores 44 points (neutral). Most supportive metric: 10Y return at 148.3 %. Weaker metric: 3Y return at 20.2 %. This suggests stronger long-term than short-term performance.
Stability scores 87 points (very strong). Best-ranked metric: max drawdown (5Y) at -18.1 %. Main drag: return/volatility ratio at 0.45. Higher Stability points are better and typically reflect calmer swings and smaller drawdowns—but prices can still fall.
Trend scores 54 points (neutral). Key strength: trend strength at 0.84. Weaker signal: Price is about 1.3 % above SMA50.
Overall, the picture is mixed: Stability does the heavy lifting while Performance holds the score back. On a metric level, max drawdown (5Y) stands out, while 3Y return lags.
(Historical evaluation, not investment advice.)
Metrics
Stability
FAQ
- What investor type does Health Care Select Sector SPDR Fund fit best in FoxScore?
- Health Care Select Sector SPDR Fund fits a more defensive investor type in FoxScore: stability is the strongest part of the profile. That points to comparatively smaller drawdowns and calmer swings versus the universe — but prices can still fall.
- How meaningful is the available history for Health Care Select Sector SPDR Fund?
- Health Care Select Sector SPDR Fund currently has about 15 years of price history available. That covers multiple market cycles including crisis phases, making long-term interpretation of returns, drawdowns and trend shifts more reliable.
- What is FoxScore good for — and what is it not for?
- FoxScore is an analysis and comparison tool: it helps you sort assets quickly, compare profiles and spot strengths/weaknesses. It’s not a substitute for your own research or fundamental analysis, and it’s not a buy/sell recommendation.